- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom, Nucynta (tapentadol) / Collegium Pharma, Grunenthal
PHM-14 - Hard 8: Fake MUs! A Review of Atypical Opioid Medications (Gracia 1 / L3) - Sep 15, 2021 - Abstract #PAINWeek2021PAINWeek_229;
Join us for a discussion on these “atypical opioids,” including low dose naltrexone, levorphanol, tramadol, tapentadol, methadone, and, of course, buprenorphine. Learning Objectives: Differentiate atypical prescription opioid medications by chemical structure, organic or synthetic origin, mechanism(s) of action, and opioid receptor affinity Recall appropriate patient recommendations for atypical prescription opioid medications in respect to pharmacological properties Recognize common atypical prescription opioid medication products in both brand and generic names
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: Immune Effects of Low-dose Naltrexone in ME/CFS (clinicaltrials.gov) - Sep 5, 2021
P=N/A, N=30, Suspended,
Learning Objectives: Differentiate atypical prescription opioid medications by chemical structure, organic or synthetic origin, mechanism(s) of action, and opioid receptor affinity Recall appropriate patient recommendations for atypical prescription opioid medications in respect to pharmacological properties Recognize common atypical prescription opioid medication products in both brand and generic names Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022
- |||||||||| Trial initiation date: Psychobiological Mechanisms Underlying Chronic Pain (clinicaltrials.gov) - Aug 18, 2021
P=N/A, N=100, Not yet recruiting,
Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022 Initiation date: Jan 2021 --> Aug 2021
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Preclinical, Journal: LDN Protects Bone Property Deterioration at Different Hierarchical Levels in T2DM Mice Bone. (Pubmed Central) - Aug 17, 2021
The bone size (bone geometry) was increased in the case of HFD-induced T2DM bone; however, LDN cannot protect to increase the bone size in the T2DM mice bone. In conclusion, LDN can be used to control the T2DM-affected bone properties at different hierarchical levels.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Clinical, Journal: Survey-reported medication changes among older adults during the SARS-CoV-2 (COVID-19) pandemic. (Pubmed Central) - Jul 30, 2021
In this community-based survey sample of over one thousand older adults, only a small percentage (2.7%; n = 31) reported any changes to medications during the pandemic. As essential workers during this crisis, pharmacists have played a critical role in providing medication information and continued access.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Clinical, Journal: Utilization of Low-Dose Naltrexone for Burning Mouth Syndrome: A Case Report. (Pubmed Central) - Jul 30, 2021
Low-dose naltrexone has been reported to provide analgesia in central sensitization states and was successful in reducing pain severity in our patient. We conclude that low-dose naltrexone may be a therapeutic option for patients with burning mouth syndrome who are refractory to conventional therapies.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion, Enrollment change, Trial completion date: EMCS-NDPH: Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children (clinicaltrials.gov) - Jul 29, 2021
P1/2, N=40, Completed,
We conclude that low-dose naltrexone may be a therapeutic option for patients with burning mouth syndrome who are refractory to conventional therapies. Active, not recruiting --> Completed | N=150 --> 40 | Trial completion date: May 2021 --> Nov 2020
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Clinical, Review, Journal: Opioid-induced hypogonadism: pathophysiology, clinical and therapeutics review. (Pubmed Central) - Jul 15, 2021
Opioid clinical use in pain therapy is indispensable. However, the resultant sexual endocrinopathy cannot be overlooked and hence hormonal replacement therapy with regular monitoring of the patients represents a potential therapeutic strategy while avoiding opioids in patients with guaranteed long therapeutic exposure and switching to using low dose naltrexone as alternative represents a possible prophylactic measure to ensure therapeutic compliance and secure a good life quality of patients.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Review, Journal: Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review. (Pubmed Central) - Jul 11, 2021
These effects appear to unique at low dosage compared to dosage for food and drug administration approved use for alcohol and opioid dependence. We review the evidence that LDN has shown more than promise and should be further investigated in clinical practice.
- |||||||||| ketamine / Generic mfg., gabapentin / Generic mfg.
Review, Journal: Complex Regional Pain Syndrome: A Comprehensive Review. (Pubmed Central) - Jun 25, 2021
There have been supporting findings in the use of short-course steroids, bisphosphonates, gabapentin, and ketamine...Future studies are warranted to better understand this syndrome. This will provide an opportunity for better prevention, diagnosis, and treatment of CRPS.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy (clinicaltrials.gov) - Jun 24, 2021
P2, N=35, Recruiting,
This will provide an opportunity for better prevention, diagnosis, and treatment of CRPS. Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Apr 2021 --> Sep 2021
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Clinical, Journal: Efficacy of Low Dose Naltrexone in Psoriasis. (Pubmed Central) - Jun 22, 2021
It requires further studies for long-term response. Key Words: Naltrexone, Psoriasis, PASI, DLQI, BSA.
- |||||||||| pregabalin / Generic mfg., gabapentin / Generic mfg., duloxetine / Generic mfg.
Select Opioid Antagonist for Diffuse Body and Joints Pain. An Alternative Modality Versus Opioid Agonist? (Mezzanine 16AB) - Jun 20, 2021 - Abstract #ASA2021ASA_1878;
Over the counter topical cream and spray, prescription diclofenac gel, lidocaine and compounding ointments only provided inadequate and momentary pain relief...Patient discontinued acetaminophen, ibuprofen and naproxen recently due to ineffectiveness...Patient continued on duloxetine daily and tizanidine as needed to relieve muscle spasms, diffuse body, joints, neck and back pain...Patient tried tramadol and acetaminophen with codeine but stopped due to nausea and constipation without significant benefit...Consider pregabalin in lower dose cautious titration since she could not tolerate adverse effects of gabapentin...6. Follow up with anesthesiology pain medicine center for re-evaluation and potential spinal or peripheral neuromodulation approach if indicated later.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
L216. Select Opioid Antagonist for Diffuse Body and Joints Pain. An Alternative Modality Versus Opioid Agonist? (Mezzanine 16AB) - Jun 20, 2021 - Abstract #ASA2021ASA_1877;
Follow up with anesthesiology pain medicine center for re-evaluation and potential spinal or peripheral neuromodulation approach if indicated later. Summarize the proposed mechanism of action on Low Dose Naltrexone (LDN) Describe clinical efficacy of LDN in chronic diffuse body and joints pain Appraise indication of LDN as multimodal analgesia in fibromyalgia Interpret the current diagnostic criteria of Fibromyalgia
- |||||||||| pregabalin / Generic mfg., gabapentin / Generic mfg., duloxetine / Generic mfg.
Select Opioid Antagonist for Diffuse Body and Joints Pain. An Alternative Modality Versus Opioid Agonist? (Mezzanine 16AB) - Jun 20, 2021 - Abstract #ASA2021ASA_1370;
Over the counter topical cream and spray, prescription diclofenac gel, lidocaine and compounding ointments only provided inadequate and momentary pain relief...Patient discontinued acetaminophen, ibuprofen and naproxen recently due to ineffectiveness...Patient continued on duloxetine daily and tizanidine as needed to relieve muscle spasms, diffuse body, joints, neck and back pain...Patient tried tramadol and acetaminophen with codeine but stopped due to nausea and constipation without significant benefit...Consider pregabalin in lower dose cautious titration since she could not tolerate adverse effects of gabapentin...6. Follow up with anesthesiology pain medicine center for re-evaluation and potential spinal or peripheral neuromodulation approach if indicated later.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
L137. Select Opioid Antagonist for Diffuse Body and Joints Pain. An Alternative Modality Versus Opioid Agonist? (Mezzanine 16AB) - Jun 20, 2021 - Abstract #ASA2021ASA_1369;
Follow up with anesthesiology pain medicine center for re-evaluation and potential spinal or peripheral neuromodulation approach if indicated later. Summarize the proposed mechanism of action on Low Dose Naltrexone (LDN) Describe clinical efficacy of LDN in chronic diffuse body and joints pain Appraise indication of LDN as multimodal analgesia in fibromyalgia Interpret the current diagnostic criteria of Fibromyalgia
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Buprenorphine and Low dose naltrexone: Perioperative implications (Upper 7AB) - Jun 20, 2021 - Abstract #ASA2021ASA_1053;
Summarize the proposed mechanism of action on Low Dose Naltrexone (LDN) Describe clinical efficacy of LDN in chronic diffuse body and joints pain Appraise indication of LDN as multimodal analgesia in fibromyalgia Interpret the current diagnostic criteria of Fibromyalgia There is no abstract associated with this presentation.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
PN220. Perioperative Issues in Chronic Pain Patients (Upper 7AB) - Jun 20, 2021 - Abstract #ASA2021ASA_1052;
Recognize adverse effects related to cannabis use and substance abuse and how they may impact perioperative pain management. Discuss perioperative issues and management in patients with intrathecal delivery systems for chronic pain.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Doctor, are tryptophan, melatonin, gaba, ashwagandha, also why they could work because they raise serotonin and LDN Low Dose Naltrexone, and have you researched the issues of Wit D3, NAC, Quercetin, Zinc, Wit C? (Twitter) - May 19, 2021
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Journal: Improvement of Hailey-Hailey disease with low-dose naltrexone. (Pubmed Central) - May 15, 2021
Secondary bacterial and viral infections are common. There is no "gold standard" treatment, although many therapeutic modalities have been proposed.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Journal: Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome. (Pubmed Central) - May 15, 2021
We hypothesize that this may be possible due to LDN operating via anti-inflammatory pathways as well as acting as an opioid antagonist. We assert that further research as it relates to LDN and SPS in addition to other chronic pain conditions is warranted.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Preclinical, Journal, IO biomarker: LOW-DOSE NALTREXONE REVERSES FACIAL MECHANICAL ALLODYNIA IN A RAT MODEL OF TRIGEMINAL NEURALGIA. (Pubmed Central) - May 14, 2021
The first dose of low-dose naltrexone or carbamazepine partially reversed facial allodynia...Spinal cord levels of BDNF and IL-10 were modulated by low-dose naltrexone. Thus, low-dose naltrexone may be suitable to relieve TN; however, the exact mechanisms need to be clarified.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: LDN-CRPS: Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome (clinicaltrials.gov) - May 6, 2021
P=N/A, N=40, Recruiting,
Thus, low-dose naltrexone may be suitable to relieve TN; however, the exact mechanisms need to be clarified. Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
[VIRTUAL] The Multiple Applications of Naltrexone in Medical and Psychiatric Disorders () - May 2, 2021 - Abstract #APA2021APA_1318;
Naltrexone has comprehensive potential in medicinal therapy; it has a variety of therapeutic effects which have yet to be explored. The authors concluded that extensive long-term studies/ clinical trials are needed to better understand the role of naltrexone in terms of its proper dosage and guidelines of its usage in various medical and psychiatric conditions.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion: Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia (clinicaltrials.gov) - Apr 8, 2021
P2, N=50, Completed,
Future controlled studies with more robust sample sizes, particularly in humans, are needed to fully elucidate its potential in cancer therapy. Active, not recruiting --> Completed
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Review, Journal: Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review. (Pubmed Central) - Feb 4, 2021
It can offer additional management options, as orofacial pain conditions share characteristics with other chronic pain disorders. Owing to the size and heterogeneity of the studies, more large-scale studies are needed, along with additional studies assessing orofacial pain response to low-dose naltrexone.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open: Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome (clinicaltrials.gov) - Feb 2, 2021
P2, N=60, Recruiting,
Owing to the size and heterogeneity of the studies, more large-scale studies are needed, along with additional studies assessing orofacial pain response to low-dose naltrexone. Not yet recruiting --> Recruiting
- |||||||||| naltrexone / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: Fibromyalgia and Naltrexone: The FINAL Study (clinicaltrials.gov) - Jan 13, 2021
P2, N=100, Recruiting,
Not yet recruiting --> Recruiting Trial completion date: Jun 2022 --> Jun 2023 | Initiation date: May 2020 --> Jan 2021 | Trial primary completion date: May 2022 --> Jan 2023
|
